Abbott: Clinical Trials

72 trials sponsored by Abbott, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

59 completed, 10 terminated, 2 withdrawn, 1 unknown. 72 Phase 1, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 172Completed 59, Terminated 10, Withdrawn 2, Unknown 1
Phase 210Completed 6, Terminated 4

Follow Abbott: new trials by email

Trials (filtered) newest first · largest first

All 72 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects
Cortiment, Budesonide - Healthy Subjects, Human Volunteers
Phase 1CompletedAbbott562021-07-122022-08-29
Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects
Moksi® 400mg Tablet, Drug: Avelox® 400Mg Tablet - Bioequivalence
Phase 1CompletedAbbott382019-03-272022-04-01
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Veliparib, Topotecan - Ovarian Cancer
Phase 1 / Phase 2CompletedVejle Hospital222012-11-012015-06-10
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
ABT-126, Placebo - Alzheimer's Disease
Phase 1CompletedAbbott202011-11-012012-05-02
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Veliparib - Recurrent, Epithelial Ovarian Cancer
Phase 1 / Phase 2CompletedVejle Hospital492011-11-012016-11-16
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
ABT-614, Placebo Comparator - Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Phase 1CompletedAbbott162011-11-012012-08-22
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
linifanib - Advanced or Metastatic Solid Tumors
Phase 1TerminatedAbbott142011-10-012012-08-28
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
ABT-888/Bortezomib - Multiple Myeloma
Phase 1CompletedAHS Cancer Control Alberta192011-10-012017-09-25
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
[14C]linifanib, ABT-869, linifanib - Advanced Solid Tumors
Phase 1TerminatedAbbott32011-08-012012-09-21
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Linifanib, Rifampin - Advanced Solid Tumors
Phase 1CompletedAbbott142011-05-012011-11-02
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
linifanib - Advanced Solid Tumors
Phase 1CompletedAbbott132011-05-012012-03-23
A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
SLV354 - Schizophrenia
Phase 1CompletedAbbott182011-05-012012-09-18
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
briakinumab - Moderate to Severe Plaque Psoriasis
Phase 1WithdrawnAbbott122011-04-012011-10-21
Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.
ABT-SLV361, placebo - Hypogonadal Males
Phase 1CompletedAbbott2011-04-012011-11-03
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
ABT-888, mFOLFOX-6 - Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletedGeorgetown University642011-01-032025-11-06
Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut
FITC-Adalimumab - Crohn's Disease
Phase 1 / Phase 2CompletedUniversity of Erlangen-Nürnberg Medical School252011-01-012012-09-14
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
ABT-652, Placebo - Sleep Disorder
Phase 1CompletedAbbott362010-08-012011-07-04
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
ABT-267, Placebo, Blood Sample Collection - HCV Infection
Phase 1CompletedAbbott1372010-08-012012-01-24
Influence of Male Hormones on Regional Fat Metabolism
Leuprolide, Testosterone - Obesity
Phase 1CompletedMayo Clinic392010-06-012014-05-14
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
ABT-869, ketoconazole - Solid Tumors
Phase 1CompletedAbbott122010-05-012011-07-26

Showing 20 of 72. Sign in to see all of them.

Conditions studied

Hepatitis C (11)  ·  HIV Infections (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Alzheimer Disease (2)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lung Neoplasms (2)  ·  Lymphoma (2)  ·  Multiple Myeloma (2)  ·  Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Recurrence (2)  ·  Schizophrenia (2)  ·  AIDS-Related Complex (1)

Interventions

linifanib (6)  ·  ABT-072 (5)  ·  ABT-126 (5)  ·  Ketoconazole (4)  ·  dasabuvir (4)  ·  navitoclax (4)  ·  ABT751 (3)  ·  Lopinavir (3)  ·  Ritonavir (3)  ·  paritaprevir (3)  ·  veliparib (3)  ·  2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (2)  ·  Bevacizumab (2)  ·  Carboplatin (2)  ·  Docetaxel (2)

Countries

United States (57)  ·  Canada (4)  ·  United Kingdom (3)  ·  Denmark (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Germany (1)  ·  India (1)  ·  Ireland (1)  ·  Pakistan (1)

Top investigators

Daniel Cohen, MD (4)  ·  Mark D. McKee, MD (3)  ·  Isabelle A Gaultier, M.S., IBMH (2)  ·  Mihail Obrocea, MD (2)  ·  Adebayo Lawal, M.D. (1)  ·  Anders Jakobsen, DMSc (1)  ·  Anders Jakobsen, MD, DMSc (1)  ·  Andrew Campbell, MD (1)  ·  Angela Nilius, MD (1)  ·  Anil Singhal, PhD (1)  ·  Beatrice Rendenbach-Mueller, PhD (1)  ·  Bela Denes, MD (1)  ·  Cathey Powers, MD (1)  ·  Daniel Cohen (1)  ·  David A Williams, MD (1)

Results publications

PMID 19440247, PMID 21377273, PMID 23147218, PMID 25451055, PMID 30104007, PMID 33849298

NIH funding

2008 (2), 2009 (1), R01DK045343 (1)